In October 2024, the Ministry of Health of the Russian Federation released the Clinical Guidelines for Non-alcoholic Fatty Liver Diseases developed by professional organizations such as the Liver Research Society, the Gastroenterology Association, and the Endocrinology Association, and approved by the Scientific and Practical Council of the Ministry of Health. “For NAFLD (NASH) patients with moderate to severe elevated ALT, it is recommended to prescribe a dose of 75-150mg/day of Bicyclol for 24 weeks to reduce disease activity” (Evidence level I, Recommendation B).

Bicyclol was registered and marketed in Russia in August 2015, and has been included in Guidelines for Diagnosis, Treatment, and Prevention of Viral Hepatitis in Armed Forces, Drug-Induced Liver Injuries (Clinical Guidelines for Physicians) and Clinical Guidelines for Non-alcoholic Fatty Liver Diseases.

Link of Russian MoH: https://cr.minzdrav.gov.ru/schema/748_2

Link of Liver Research Society: https://rsls.ru/files/KRNGBP2024.pdf